Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.

By M. Higashi, David L. Veenstra, L. M. Kondo, A. Wittkowsky, S. Srinouanprachanh, F. Farin, A. Rettie. Journal of the American Medical Association (JAMA), 2002

1,079 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Pharmacology

View Paper: https://www.semanticscholar.org/paper/0b71384185a73b76b9ac86eebbd2cf8f3d5162e3

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

U. Meyer
Shiew-Mei Huang
Myong‐Jin Kim
Atiqur Rahman
L. Lesko

Citations in the corpus

A Regulatory Science Perspective on Warfarin Therapy: A Pharmacogenetic Opportunity (2009, methodology): “By using time-to-event analyses, these investigators determined that patients with one variant allele of CYP2C9 needed a longer time (a median difference of 95 days) than wild-type patients to achieve stabilization of warfarin dose and were at a higher risk for serious or life-threatening bleeds.(11”
Clinical Pharmacogenetics Implementation consortium Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin Dosing (2011, neutral): “[70] high”
Polymorphism of human cytochrome P450 enzymes and its clinical impact (2009, neutral): “…et al., 2004) *9 752A>G 10535A>G H251R (Blaisdell et al., 2004) *10 815A>G 10598A>G E272G (Blaisdell et al., 2004) *11Aa 1003C>T 42542C>T R335W ↓ ↓ (Higashi et al., 2002) *11Ba 1003C>T −2665_–2664delTG; −1188T>C; 42542C>T R335W ↓ (King et al., 2004) *12 1465C>T 50338C>T P489S ↓ (Blaisdell…”